Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Amarin Corporation plcFebruary 25, 2021 GMT
Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact
Received Positive CHMP Opinion for VAZKEPA ®
in Europe and Continue to Advance Commercial Launch Plans for Europe
Management to Host Conference Call Today at 7:30 a.m. ET
DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter and year ended December 31, 2020 and provided an update on company operations.
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of .
News Category Global Banking & Finance Reviews
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 21, 2021 Amarin Corporation plc (NASDAQ:AMRN) today announced that the Chinese Society of Cardiology (CSC) has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the
Chinese Journal of Cardiovascular Diseases. The guideline authors include “icosapent ethyl 2 grams twice a day (as studied in REDUCE-IT